Trial Profile
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NEO-Nal- IRI Study
- 20 Jan 2024 Results assessing safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium
- 01 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology